Introduction
Kaposi's sarcoma-associated virus (KSHV) is an oncogenic virus responsible for all epidemiologic forms of Kaposi's sarcoma (KS), a multifocal endothelial cell tumor (Chang et al., 1994) . Infection with this g2-herpesvirus precedes and predicts the development of KS in human immunodeficiency virus-infected patients and KS remains the most common AIDS-related malignancy Whitby et al., 1995; Gao et al., 1996) . Other forms of KS include: 'classic' KS that occurs primarily in elderly men of Mediterranean descent; 'iatrogenic' KS in solid organ transplant recipients (Civati et al., 1988; Franceschi and Geddes, 1995) ; and 'endemic' KS, a form prevalent in Africa that targets younger populations. Endemic or 'African' KS is much more aggressive and common than classic KS and can occur independent of HIV-1 coinfection. In eastern and southern Africa, a lymphadenopathic form of KS makes up 25-50% of soft-tissue sarcomas in children and accounts for 2-10% of all childhood cancers (Wabinga et al., 1993; Ziegler and Katongole-Mbidde, 1996) . As a lymphotropic virus, KSHV can also be found in various cell types of hematopoietic origin. In particular, it is thought to play an essential role in the development and overall biology of a non-Hodgkin's lymphoma, called primary effusion lymphoma (PEL). PEL is characterized by lymphomatous effusions of various serous cavities, often in the absence of a definable mass. The descriptor 'primary' is used to differentiate it from effusions that can secondarily occur with other types of lymphoma. (Cesarman et al., 1995; Soulier et al., 1995; Dupin et al., 2000) .
Over the millenia, KSHV has managed to acquire an astounding number of genes that have homologues in the human genome (Cesarman et al., 1996; Chang et al., 1996; Russo et al., 1996; Cheng et al., 1997; Guo et al., 1997; Neipel et al., 1997; Nicholas et al., 1997a, b; Sarid et al., 1997; Swanton et al., 1997; Nicholas et al., 1998; Wong, 1998) . Broadly speaking, they encode proteins involved in angiogenesis, inflammation, and the cell cycle. One that is clearly involved in the first (and quite possibly all three) is the KSHV G-protein-coupled receptor (vGPCR) . Unlike its human homologue (CXCR1 and CXCR2) and its herpesvirus saimiri homologue (ECRF3), vGPCR is not agonist-dependent. It signals constitutively as does the viral GPCR encoded by ORF 74 of murine gammaherpesvirus 68 and many other GPCRs associated with human disease (Ahuja and Murphy, 1993; Coughlin, 1994; Cesarman et al., 1996; Spiegel, 1996; Arvanitakis et al., 1998; Wakeling et al., 2001) . For vGPCR, this constitutive activity is largely due to abnormal transmembrane helices 2 and 3 as well as its cytoplasmic tail (Ho et al., 2001; Schwarz and Murphy, 2001) ; and although its N terminus is involved in ligand binding, it is not necessary for constitutive signaling by vGPCR (Ho et al., 1999; . Interestingly, despite being constitutively active, vGPCR retains the ability to bind to various chemokines that result in up-or downregulation of signaling (Geras-Raaka et al., 1998a-d; Gershengorn et al., 1998; Rosenkilde et al., 1999; . KSHV vGPCR has been characterized as a viral oncogene by virtue of its ability to cause transformation in fibroblast and primary endothelial cells as well as KSlike tumors in transgenic mice (Arvanitakis et al., 1997; Yang et al., 2000; Bais et al., 2003; Guo et al., 2003; Montaner et al., 2003) . In the two transgenic mouse models, the expression of vGPCR from relatively few endothelial or hematopoietic cells can cause endothelial cell outgrowth involving uninfected cells; this phenomenon is consistent with the observed biology of KS where a variable proportion of the proliferating cells are actually infected, and even fewer express lytic genes like vGPCR. Clearly, KSHV infection results in potent paracrine effects on surrounding cells, and vGPCR signaling is now thought to mediate at least some of these.
Aside from some excellent work in endothelial cells, monocytes, and T cells (Couty et al., 2001; Montaner et al., 2001; Schwarz and Murphy, 2001; Bais et al., 2003) , much prior work with vGPCR has been carried out in cell lines that, although very informative, are not cell types naturally infected by KSHV in vivo. Since KSHV is present in PEL cells and various hematopoietic cells are known to harbor and produce new KSHV virions, it is important to study vGPCR signaling in the specific context of a KSHV-infected hematopoietic line. We have recently described the derivation of a PEL cell line that can be made to overexpress vGPCR via a tetracycline-inducible promoter (Cannon et al., 2003) . An inducible promoter was necessary because we found that standard constitutive overexpression of vGPCR was toxic to lymphocytes. Our results showed that vGPCR constitutively activates the mitogen-and stressactivated kinases ERK-1/2 and p38 in PEL cells. Furthermore, vGPCR activates transcription from AP-1, NFkB, CREB, and NFAT-responsive promoters, thereby displaying broad signaling potential to affect both cellular and viral transcription patterns. We also showed that vGPCR can activate transcription from the KSHV ORF 50 and ORF 57 promoters, while Chiou et al. discovered that vGPCR can upregulate transcription via the T1.1/PAN, the K1, and the LLP latency leader promoters. In addition, vGPCR overexpression leads to increased PEL cell elaboration of KSHV vIL-6 and vascular endothelial growth factor (VEGF), two cytokines vital to the phenotype of KSHV-mediated tumors (Masood et al., 1997; Samaniego et al., 1998; Jones et al., 1999; Chiou et al., 2002) .
Using vGPCR-mediated activation of various transcription factors as readout for vGPCR activity, we have designed experiments to determine which are the dominant signaling pathways used by vGPCR in PEL cells. vGPCR is a broadly signaling molecule and a potential target for therapeutic intervention; but since the function of most signaling molecules is cell type dependent, it is crucial to understand what pathways are utilized to mediate downstream molecular events and any vGPCR-induced changes in cell phenotype or viral transcription patterns. Using a combination of pharmacologic enzyme inhibitors and plasmid constructs, we have determined that in PEL cells, vGPCR couples to both Gq-and Gi-type G proteins and that signaling by both these routes contributes to the activation of NFAT, AP-1 and CREB; the latter two are also dependent on a phosphatydilinositol 3 0 -kinase (PI3K)-Akt axis. Furthermore, signaling by Gq downstream to NFAT, AP-1, and CREB is at least partially mediated by ERK-1/2, whereas Gq-mediated induction of NFkB activity is not. Despite other studies showing involvement of PI3K/Akt in vGPCR activation of NFkB, we saw no evidence of this pathway in PEL cells (Couty et al., 2001; Montaner et al., 2001 ). In addition, we have shown that vGPCR activity activates the Src-family kinase Lyn via a Gi-PI3K-dependent route. In short, we have dissected the proximal signaling events involved in vGPCR activation of these various transcription factors in PEL cells.
Results

KSHV vGPCR signals via both Gq and Gi in PEL cells to activate several transcription factors
Depending on the cell model used, vGPCR has been shown to be capable of signaling via both Gq and Gi. Utilizing our recently established doxycycline-inducible vGPCR-expressing PEL cell line BC3.14, we have shown that vGPCR activates multiple transcription factors when assessed by luciferase reporter assays. Using these as readout, we sought to establish if coupling to Gq and/ or Gi could explain vGPCR's downstream effects in this hematopoietic cell line. Figures 1a and b show that vGPCR-induced activation of AP-1, NFAT, and CREB is at least partially mediated by Gi in that activation is inhibited by the pertussis toxin by approximately 30-50%. vGPCR activation of NFkB, however, is unaffected by the pertussis toxin (100 ng/ml). To support these results, we assessed the effects of coexpression of a scavenger of bg subunits, the G protein a subunit of retinal transducin (a t ) (Federman et al., 1992) . Figures  1c-f show that vGPCR-induced AP-1, NFAT, and CREB activation is inhibited by small amounts of pcDNA3.1-a t (as little as 1/10th the amount of input transcription factor-luciferase reporter plasmid). In contrast to the work by Shepard et al. (2001) in HeLa cells, vGPCR activation of NFkB is unaffected by pcDNA3.1-a t . Since it is now known that Gq proteins can signal via their bg subunits, it is possible that the dramatic inhibition of AP-1, CREB, and NFAT caused by a t signifies a contribution of both Gq and Gi proteins. Nonetheless, these results are consistent with the pertussis toxin experiments in that Gi coupling appears not to be substantially involved in NFkB transcriptional activity mediated by vGPCR in this cell type. To determine whether Gq coupling could contribute to the activation of these transcription factors in PEL cells by vGPCR, we expressed increasing amounts of a constitutively active Gq mutant, Gq(Q209L), along with the transcription factor reporters ( Figure 2 ) (Wu et al., 1992) . Cotransfection with pcDNA3.1-aq(Q209L) in as little as 1/5th the amount of input reporter plasmid caused activation of AP-1 and NFAT of approximately fourfold. In the case of NFkB and CREB, activation was achieved with 1/10th the amount of input luciferase reporter plasmid. Together, these results support the notion that, unlike the case in endothelial cells (Couty et al., 2001) , vGPCR coupling to Gi does not contribute significantly to NFkB activation. It is important to note that as designed, these experiments cannot completely rule out some Gi-mediated NFkB activation. That would require attaining and verifying maximal suppression of Gq function (and any other non-Gi G proteins). However, our results do show that Gi contribution to vGPCR-mediated NFkB activation is overwhelmed by non-Gi G proteins, likely Gq.
KSHV vGPCR signals via a Gi-PI3K/Akt axis to activate AP-1 and CREB, but not NFkB or NFAT in PEL cells
It has been recently shown that both Gq-and Gicoupled GPCRs can activate PI3K and its main effector, Akt (Murga et al., 1998) . More specifically, KSHV vGPCR promotes cell survival by activating PI3K/Akt in a manner dependent on bg subunits of both pertussissensitive and -insensitive G proteins (Couty et al., 2001; Montaner et al., 2001) . Furthermore, vGPCR induction of NFkB in endothelial lines is dependent on PI3K/Akt Figure 1 KSHV vGPCR signals via both pertussis-sensitive and -insensitive pathways in PEL cells. BC3.14 cells were transfected with the various transcription factor-luciferase constructs as shown (10 mg) and plated in 24-well plates. Doxycycline (black bars) was added where indicated to induce the expression of vGPCR. Cells were harvested after 48 h incubation at 371C with 5% CO 2 . Luciferase assays were performed and the results were normalized to baseline values in the absence of doxycycline. (a,b) vGPCRinduced activation of AP-1, NFAT, and CREB is inhibited by pertussis (100 ng/ml Â 24 h), whereas NFkB is not. (c-f) Reporter constructs were cotransfected with increasing amounts of atransducin (pcDNA3.1-a (t) to scavenge bg subunits (0, 1, 2, and 5 mg). vGPCR-mediated activation of AP-1, NFAT, and CREB was inhibited, whereas NFkB was not. Data shown are triplicate transfections for each point and are representative of at least three independent experiments. * indicates a significant decrease from baseline doxycycline-induced (i.e. vGPCR expressing) value with Pp0.05. (g) Controls for reporter constructs. pTA-Luc is a negative control for AP-1, NFkB, and NFAT constructs. pFC2-dbd serves as a control for the CREB reporter. (h) To show that vGPCR expression has no independent effect on the CMV promoter-driven constructs used in these studies (e.g., pcDNA3.1-a t ), BC3.14 cells were transfected with pCMV-bGAL, then split, and subjected to 2 mg doxycycline where indicated. bGAL expression was measured after 48 h using equal amounts of protein extract. A similar control transfection was performed with pRL-TK to ensure that vGPCR has no effect on the herpes simplex virus thymidine kinase-derived promoter used for renilla expression (Montaner et al., 2001; Pati et al., 2001) . Given our observation that vGPCR-mediated activation of NFkB is not predominantly Gi-mediated in PEL cells ( Figure  1b , f), we questioned whether PI3K/Akt was involved. BC3.14 cells were transfected with the indicated Figure 2 Constitutively active Gaq activates AP-1, NFAT, CREB, and NFkB in PEL cells. (a) BC3.14 cells growing in the log phase were transfected with the indicated transcription factorluciferase reporter construct (10 mg) along with increasing amounts of pcDNA3.1-aq (Q209L) (0, 1, and 2 mg). An Empty pcDNA3.1( þ ) plasmid was used to equalize total DNA per transfection. A constant amount of pRL-TK (3 mg) encoding renilla luciferase was used to correct for transfection efficiency. After 48 h, cells were harvested and firefly and renilla luciferase assays were performed. The results were corrected for renilla expression and then normalized to non-aq(Q209L)-expressing samples. Black bars, AP-1; thin hatch, NFAT; thick hatch, NFkB; gray bar, CREB. *, Pp0.05 relative to the baseline value. For CMV promoter and pRL-TK negative controls, see Figure 1h Figure 3 vGPCR signals via both ERK-1/2-and PI3K-dependent pathways. (a-d) BC3.14 cells growing exponentially were transfected with the indicated transcription factor-luciferase reporter (10 mg). Doxycycline was added where indicated to induce expression of vGPCR. Cells were harvested after 48 h. Luciferase assays were performed and the results were normalized to baseline values in the absence of doxycycline. Gray bars, no doxycycline; black bars, 2 mg/ml doxycycline. (a, b) vGPCR-induced activation of AP-1 and CREB is partially inhibited by PI3 K inhibitor wortmannin (100 nm Â 24 h), whereas activation of NFAT and NFkB is not. (c, d) vGPCR-induced activation of AP-1, NFAT, and CREB but not NFkB is partially blocked by ERK inhibitor PD 98059 (50 mm Â 24 h). The data shown are triplicate transfections for each point and are representative of at least three independent experiments. * indicates a significant decrease from baseline doxycycline-induced (i.e. vGPCR expressing) value with Pp0.05. (e, f) BC3.14 cells were incubated with or without doxycycline for 48 h. At 45 min prior to cell harvest, various enzyme inhibitors were added. Lysates were used to perform Western blots for phosphorylated Akt or ERK-1/2 as shown. The blots were stripped and reprobed with antibody to total enzyme. PTX, pertussis 100 ng/ml; wort, wortmannin 100 nm; PP2 used at 5 mm; PD, PD 98059 50 mm transcription factor reporter construct (Figure 3a, b) , plated with or without doxycycline, and then subjected to the PI3K inhibitor wortmannin at a dose of 100 nm for 24 h. Luciferase assays show that although PI3K/Akt contributes to vGPCR-mediated AP-1 and CREB activity, it does not play a role in vGPCR-mediated NFkB or NFAT activation in this cell type. Of note, wortmannin doses as high as 500 nm produced similar effects (data not shown). The PI3K inhibitor LY294002 (10-20 mm) also failed to inhibit NFkB activation (data not shown). Figure 3e shows that vGPCR-induced Akt phosphorylation, and hence activation, is inhibited by pertussis, and as expected, by the PI3K inhibitor wortmannin. Taken together, these data show that the pertussis sensitivity of vGPCR-mediated AP-1 and CREB activation, shown in Figure 1 , can be explained by a Gi-PI3K/Akt axis, and that although NFAT activation is at least partially mediated by Gi, this does not require PI3K/Akt. This is not surprising since NFAT activation is calcium dependent and it is known that Gi can mediate calcium-dependent signaling in various models. Our findings are, however, in contrast with other works that show that vGPCRmediated NFAT activation in KSIMM cells is PI3K/ Akt dependent (Pati et al., 2003) .
ERK-1/2 activation by vGPCR contributes to the activation of AP-1, CREB, and NFAT in a non-Gidependent manner, but has negligible contribution to NFkB activation Constitutive activity of ERK-1/2 is associated with oncogenesis in both GPCR-dependent and -independent models (Dhanasekaran et al., 1995) . It is known that KSHV vGPCR activates ERK-1/2 in COS-7, but not in HEK 293 cells (Bais et al., 1998; Sodhi et al., 2000) , and we have recently shown constitutive activation of ERK-1/2 and p38 by vGPCR in PEL cells (Cannon et al., 2003) . To determine which vGPCR downstream events required ERK-1/2 activation, BC3.14 cells were transfected with the indicated reporter constructs in Figure 3 and subjected to 50 mm PD98059, a specific inhibitor of ERK-1/2. Luciferase assays show that ERK-1/2 contributes to the activation of AP-1, CREB, and NFAT, but not to NFkB. Figure 3b shows, by Western blot, that vGPCRinduced phosphorylation of ERK-1/2 is not inhibited by either the PI3K inhibitor wortmannin or by pertussis. This is in contrast to data from Smit et al. (2002) that show Gi-mediated ERK-1/2 activation in COS-7 cells. Although our data do not rule out minor Gi-mediated contribution to vGPCR-mediated ERK-1/2 activation in PEL cells, they do show that it is likely negligible compared to that mediated by Gq coupling. Furthermore, it means that vGPCR-induced activity of AP-1, CREB, and NFAT is mediated cooperatively by Gi (i.e. it is partially pertussis sensitive) and by Gq (via a nonpertussis sensitive ERK-1/2-dependent limb).
KSHV vGPCR activates endogenous Lyn tyrosine kinase via a Gi-and PI3K-dependent route that in turn contributes to AP-1 and CREB activation in PEL cells Certain GPCRs are known to activate mitogen-activated protein kinase cascades via the Src-family kinases through Gq and/or Gi pathways, depending on the cell type and the receptor studied (Daub et al., 1996; Luttrell et al., 1996; Eguchi et al., 1998; Igishi and Gutkind, 1998; Ma et al., 2000; Pierce et al., 2001) . More specifically, vGPCR can activate the Src-related kinase, Lyn, via a proline-rich tyrosine kinase 2 (Pyk2) in 293T cells (Munshi et al., 1999) . For these reasons, we looked for evidence of vGPCR activation of Src-family members in PEL cells. Figures 4a  and b show that vGPCR-induced activation of AP-1 and CREB is partially reversed by the specific Src-family kinase inhibitor PP2 at standard concentrations (5 mm). As shown, NFAT and NFkB activation were unaffected and actually trended upward using the same compound. Of note, doses of PP2 up to 15 mm yielded similar results; higher doses were generally toxic (data not shown). To support this pharmacologic data, we also used the doubly mutated Src-dominant-negative (DN) construct (K296R/ Y528F, Upstate) in assays for vGPCR-mediated AP-1 and NFkB activation. Consistent with the PP2 data, Figures 4c  and d show that increasing amounts of transfected Src-DN partially inhibited AP-1 activation, but not NFkB. Notably, both NFAT and NFkB were unaffected by either Src inhibition or PI3K/Akt inhibition, whereas AP-1 and CREB were affected by both (see Figures 3a, b, 4a-d) ; these findings suggested that PI3K/Akt and Src may be in the same pathway. Indeed, using enolase as an exogenous substrate, we show that not only does vGPCR potently activate Lyn kinase in serum-starved PEL cells but it also does so in a pertussis-and wortmannin-sensitive manner (Figure 4e ). Taken together, these data support a Gi-PI3K/Akt-Src axis partially contributing to vGPCRmediated activation of AP-1 and CREB. It is interesting to note that inhibition of Src with PP2 decreases Akt phosphorylation (Figure 3e ), apparently placing Src upstream rather than downstream of PI3K/Akt; this will be discussed further below.
If, as discussed above, ERK-1/2 contributes to AP-1 and CREB activation by vGPCR in a non-Gi-dependent manner, then induction of AP-1 and CREB by the constitutively active mutant Gq(G209L) should be refractory to inhibition of the Gi-PI3K-Src axis by the Src inhibitor PP2 or the PI3 K inhibitor wortmannin. Figure 4f shows that unlike activation by vGPCR, activation of AP-1 and CREB by Gq(G209L) is not inhibited by PP2 or wortmannin but is dramatically inhibited by the ERK-1/2 inhibitor PD09859. Again, these results support the idea that AP-1 and CREB activation by vGPCR is mediated cooperatively by both Gq-Erk1/2-and Gi-PI3K-Src-dependent routes. We have also found that the effects of PD09859 to inhibit RK and pertussis to inhibit the Gi axis are additive in inhibiting vGPCR-mediated AP-1 and CREB activity; again arguing for contribution from two distinct pathways (data not shown).
Discussion
KSHV is an oncogenic virus closely linked with Kaposi's sarcoma and two lymphoproliferative disorders: PEL and multicentric Castleman's disease. Several KSHV gene products, including vGPCR, are considered viral oncogenes. Although the downstream cascades utilized by vGPCR have been studied in various cell lines, little has been performed using cells of hematopoietic origin. Lymphocytes and monocytes serve as reservoirs for KSHV infection, so understanding how vGPCR behaves in these cells is necessary to describe its role in KSHVmediated disease. Our initial studies in KSHV-positive PEL cells showed that vGPCR has potential to affect both cellular and viral transcription patterns. It is clear now that vGPCR is a promising therapeutic target for KSHV-mediated disease, but since vGPCR is a broadly signaling molecule, a rational approach to manipulating it requires a description of the predominant pathways it uses to affect transcriptional events relevant to the KSHV life cycle and the phenotype of infected cells.
Pharmacologic enzyme inhibitors as well as plasmid constructs for both gain and loss of function experiments are very useful tools to study signaling cascades. Individually, however, both pharmacologic agents and cotransfection experiments have drawbacks including possible nonspecific effects such as toxicity or interference with unknown signaling intermediates; the low Figure 4 vGPCR signals via Src-family members to activate AP-1 and CREB, but not NFAT or NFkB. (a, b) vGPCR BC3.14 cells were transfected with the indicated transcription factor reporter and plated with (black bars) or without doxycycline (gray bars). At 24 h, PP2 5 mm was added where indicated. At 48 h, cell lysates were assayed for luciferase activity and the results were normalized to baseline values in the absence of doxycycline or PP2. *, indicates a significant decrease from vGPCR-expressing, noninhibited point. (c, d) BC3.14 cells were transfected with 5 mg of reporter plasmids for AP-1 or NFkB along with increasing amounts of the CMVpromoter driven Src-DN plasmid construct (0, 5, 10, and 20 mg). An empty pcDNA3.1( þ ) plasmid was used to equalize total plasmid concentration and a constant amount of pRL-TK (3 mg) was added to control for the transfection efficiency. Doxycycline was added where indicated (black bars). The values were corrected for renilla luciferase expression and normalized to baseline nondoxycycline-induced point. Src-DN resulted in a modest AP-1 decrease, but no change in NFkB activation by vGPCR. Each bar represents triplicate transfections and the entire experiment was repeated at least three times. * indicates a significant decrease from vGPCR-expressing, non-Src-DN point. For negative control showing that vGPCR has no independent effect on CMV-derived promoter, see Figure 1h ). (e) vGPCR activates Src-family kinases. Cell lysates from BC3.14 cells þ /À doxycycline to express vGPCR were used to assay Lyn kinase activity using enolase as an exogenous substrate and [g-32 P]ATP. Chemical enzyme inhibitors were added where indicated 45 min prior to harvesting cells. PTX, pertussis, 100 ng/ml; Wort, wortmannin, 100 nm; PD, PD90859, 50 mm. (f) Activation of AP-1 and CREB by Gq is not dependent on PI3K or Src, but is ERK-1/2 dependent. BC3.14 cells were transfected with luciferase reporter construct as indicated þ /À cotransfection with 3 mg pcDNA3.1-Gq(Q209L) in the presence of the indicated inhibitors for 24 h. Luciferase assays were performed 48 h post transfection. White bars, no Gq(Q209L); black bars, no inhibitors added; thick hatch, PP2 (10 mm); gray bar, wortmannin (100 nm); thin hatch, PD98059 (50 mm) transfection efficiency of many hematopoietic lines also creates problems designing experiments that require multiple plasmids to be cotransfected and successfully expressed. Generally then, it is best to combine the two approaches where feasible. In the current study, we used a PEL line that requires only a tetracycline derivative to overexpress vGPCR in the context of a KSHV infection. We then use both cotransfection and chemical inhibitor assays to examine the predominant route from vGPCR to AP-1, CREB, and NFkB. Of course, binding sites for these transcription factors are found in many cellular genes and likely exist in various KSHV viral promoters, but rigorous mutational analyses remain to be carried out (Nicholas et al., 1998; Deng et al., 2002; Cannon et al., 2003) . We also assessed the vGPCR's impact on NFAT, a transcription factor that is essential to the calcium-mediated KSHV latent to lytic switch (Zoeteweij et al., 2001) .
vGPCR is known to signal constitutively and, depending on the cell type, does so via multiple G protein subtypes. For example, it appears to couple to Gq in Cos-1 and HEK 293T cells, and activates the stress-activated kinases JNK and p38 in the later (Arvanitakis et al., 1997; Bais et al., 1998; Burger et al., 1999) . In endothelial cells, vGPCR clearly signals via Gi and leads to increased cell survival (Couty et al., 2001; Montaner et al., 2001 ). In the current study using PEL cells, we show that an ability to couple with Gq partially explains vGPCR-induced activation of AP-1, CREB, and NFAT via an ERK-1/2-dependent route (Figures 2;  and 4f ). Since we saw no evidence for pertussis sensitivity of ERK-1/2 activation (Figure 3f) , we conclude that the pertussis sensitivity of AP-1, CREB, and NFAT activation by vGPCR represents a largely independent route from a Gi-type G protein ( Figure  1a, b) . Some crosstalk, however, between the Gq-and Gi-coupled limbs is evident since inhibition of ERK-1/2 with PD98059 led to an obvious inhibition of vGPCRinduced phosphorylation of Akt as seen in Figure 3e . Our data support the apparent ERK-1/2-dependent Akt activation by vGPCR that was first reported by Smit et al. (2002) using the ERK-1/2 inhibitor U0126 in COS-7 cells .
As noted above, both Gq and Gi can signal via PI3K/ Akt. We show here that the Gi-mediated activation of AP-1 and CREB is indeed inhibited by the PI3K inhibitor wortmannin, whereas activation of NFAT, although partially dependent on Gi, is not reliant on a Gi-PI3K/Akt axis as are AP-1 and CREB ( Figure  3a, b) . Although we have not ruled out the possibility of some PI3K/Akt activation by non-Gi G proteins, it does appear that the activation of ERK-1/2 is not PI3K dependent (Figure 3f) . Again, this helps to define both Gq-ERK-1/2 and Gi-PI3K/Akt routes that converge on activation of AP-1 and CREB ( Figure 5) .
The Src family of nonreceptor kinases is ubiquitous and various members contribute to cell surface receptor signaling in lymphocytes. For example, Lyn activation is thought to be a very proximal downstream event in Bcell antigen receptor (BCR) signaling; for a review, see Tamir and Cambier (1998). As mentioned above, several GPCRs are known to activate the Src-family kinases via Gq and/or Gi, and vGPCR has been shown to do so in 293T cells (Munshi et al., 1999) . Using a combination of a chemical Src-family inhibitor, PP2, and an Src-DN construct, we show that the vGPCR activation of AP-1 and CREB is partially mediated by an Src-family kinase (Figure 4a-c) . Since vGPCR activation of the Srcrelated kinase Lyn is sensitive to both pertussis and wortmannin (Figure 4e ), we show that it is a Gi-PI3K/ Akt-Src axis that contributes to AP-1 and CREB activation. Furthermore, the insensitivity of vGPCRinduced NFkB and NFAT activation to Src inhibition is consistent with their insensitivity to PI3K inhibition by wortmannin (Figures 4a, b, d; and 3a, b) . A further interesting finding was that the Src inhibitor PP2 inhibited the activation of Akt. This suggests that although PI3K appears to be upstream of Src, Src may be involved in a positive feedback loop. This possibility is not unprecedented as Lyn is thought to enhance the activity of certain PI3K isoforms in B cells; for a review, see Marshall et al. (2000) .
Interestingly, although NFkB activation by vGPCR could be explained by coupling to Gq, inhibition of Gi, PI3K/Akt or Src had no effect (Figures 1b, f; and 3b, d) . This is in contrast to the work carried out in endothelial cells and may reflect an important cell-specific difference in vGPCR signaling. Furthermore, although Gq clearly signals via ERK-1/2, this did not seem to be the pathway involved in NFkB activation (Figure 4b) . Furthermore, although NFkB activity in PEL cells is present at baseline, our studies here show that this basal activity is not mediated by Gi in that it is not pertussis sensitive (compare bars 1 and 3, Figure 1b) . NFkB is a known antiapoptotic factor in PEL cells so its activation via vGPCR requires further study, but several possibilities Pathways used by KSHV vGPCR in signaling downstream to various transcription factors. Gi contributes to vGPCRinduced AP-1 and CREB activation via a PI3K/Akt-Src axis that is not required for Gi-mediated NFAT activation. NFkB activation is predominantly mediated by Gq coupling. Gq also contributes to AP-1, CREB, and NFAT activation via ERK-1/2, which may also serve as a point of crosstalk between signaling cascades by virtue of its positive effect on Akt exist (Keller et al., 2000) : NFkB is known to be activated by certain intermediates in the MAP kinase cascade such as MAP kinase kinase-1 (MEKK1), and by phospholipase Cg (PLCg) and protein kinase C (PKC) in various models (Baeuerle and Henkel, 1994; Marshall et al., 2000) . Although both Gi and Gq coupling could feasibly activate these intermediates, the present studies argue that coupling to Gq rather than Gi is the predominant way vGPCR activates NFkB in PEL cells. Although these findings differ from those in endothelial cells, the reasons are not yet clear. One explanation may be that there are differences in the levels or isoforms of the various signaling intermediates. Polson et al. also found that vGPCR has different effects on cellular gene transcription in endothelial versus B cells, and rightly points out that this may relate to different roles for vGPCR in the pathogenesis of KSHV-mediated endothelial and lymphoproliferative lesions (Polson et al., 2002) .
KSHV vGPCR may play various roles in the pathogenesis of KSHV-mediated disease depending on the cell type infected, and the stage of disease. Dissecting vGPCR-induced signaling events will help elucidate these functions. Furthermore, if a rational targeted interference of vGPCR function is desired, it requires knowledge of cell-specific vGPCR signaling pathways to facilitate the minimization of unexpected toxicities, while maximizing the therapeutic effect. Having established a KSHV-positive PEL cell line that inducibly expresses vGPCR, we have been able to delineate some of the signaling intermediates used by this potent oncogene.
Materials and methods
Cell culture
The PEL cell line used to overexpress vGPCR (BC3. 14) was derived as previously described (Cannon et al., 2003) , and maintained in RPMI 1640 plus 40 mg/l gentamycin (Invitrogen) with 10% FBS (Atlanta Biologicals, Norcross, GA, USA) at 371C, 5% CO 2 .
Transfections
Transfections were performed on exponentially growing BC3.14 cells by electroporation (Bio-Rad Gene Pulser II) at settings of 270 mV and 975 mF in 0.8 cm cuvettes (Invitrogen), using 8 Â 10 6 cells/cuvette resuspended in 0.8 ml RPMI 1640. Cuvettes were prechilled on ice, and after transfection, cells were quickly plated in full culture medium as described above. Luciferase reporter constructs to detect transcription factor activation included pNFkB-Luc, pAP1 (PMA)-TA-Luc, pNFAT-TA-Luc, and pTA-Luc from Clontech. A dualplasmid system using pFR-Luc and pFA2-CREB was obtained from Stratagene as was the control plasmid pFC2-dbd. pcDNA3.1-aq(G209L) and pcDNA3.1-a t were obtained from Xin-Yun Huang (Federman et al., 1992; Wu et al., 1992) . We have established and shown that the control promoter constructs for all these transcription factor reporter constructs do not respond to vGPCR expression (Cannon et al., 2003) . pCMV-GAL was used as a negative control to ensure that vGPCR has no independent influence on CMV-derived promoter; activity was measured with b-Galactosidase Enzyme Assay System with Passive Lysis Buffer as per the manufacturer's protocol (Promega).
Luciferase assays
For single-plasmid transfection experiments, cells were split into two samples after transfection, plated in 24-well plates, and exposed to doses of doxycycline (Calbiochem) and/or various pharmacologic inhibitors as shown in figures. After 48 h, lysates were prepared using 1 Â Cell Culture Lysis Reagent as per the manufacturer's directions (Promega). Assays were performed using 10 ml of lysate and 50 ml of beetle luciferin in a Microtiter s Plate Luminometer (Dynex Tech., Chantilly, VA, USA), using a 10-s read time. Protein concentration was used for normalization and was determined by the Bradford method with Bio-Rad DC Protein Assay Reagent after diluting samples and standards 1 : 1 in PBS. For cotransfection experiments, the total amount of plasmid was equalized using pcDNA3.1( þ ), and 3 mg of pRL-TK (Promega) was included in each cuvette for the expression of renilla luciferase for use as control for transfection efficiency. Lysates were made with 1 Â Passive Lysis Buffer and assays were performed according to the manufacturer's protocol using Dual Luciferase kit reagents (Promega).
Western blot analysis and Src kinase assay BC3.14. cells were plated in full growth medium at 5 Â 10 5 /well of a 24-well plate and subjected to various doses of freshly resuspended doxycycline for 48 h. Samples were incubated with various enzyme inhibitors for 45 min prior to lysis with standard RIPA buffer with 1 mg/ml each of aprotinin, leupeptin, and pepstatin, 0.5 mm PMSF, and 1 mm each of NaVO 4 and NaF (Sigma). Protein was quantitated by the Bradford method and loaded onto sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) using 10-12% gels. Semidry transfer to PVDF (Millipore) was performed using transfer buffer, 48 mm Tris, 39 mm glycine, 0.037% SDS, and 20% methanol. Blots were probed with primary antibody (Ab) overnight at 41C. HRP-conjugated secondary Ab was added after washing and detected by an enhanced chemiluminescence system (ECL) (Amersham). For anti-phospho-kinase blots, the blots were stripped after detecting the phosphorylated form and reprobed with Ab to total enzyme. The following primary Ab's were used: anti-phospho-ERK1/2, anti-phospho-Akt, anti-phospho and anti-total Akt (Cell Signaling Tech.); anti-total ERK1/2-ct (Upstate).
For the in vitro Lyn kinase assay, enzyme inhibitors were added 45 min prior to lysis with modified RIPA buffer (50 mm Tris (pH 7.5), 500 mm NaCl, 10 mm MgCl 2 , 1% Triton, 0.1% SDS, 0.5% DOC, 1 mm EDTA, and protease inhibitors as above). Lysate (800 mg) was incubated overnight at 41C with 2 mg anti-Lyn(44) antibody (sc-15; Santa Cruz) and 30 ml Protein G-Plus agarose beads (Santa Cruz). Beads were washed three times in lysis buffer and twice in kinase buffer (20 mm Tris (pH 7.5), 5 mm MgCl 2 , 0.1% NP-40, 0.1 mm NaVO 4 ). Kinase reaction was performed for 15 min at 301C in 30 ml kinase buffer with 5 mm cold ATP, 3 mCi [g-32 P] ATP (3000 Ci/mmol; Amhersham), and 3 mg of acid-denatured enolase (Sigma). The reaction was stopped with loading buffer and boiled for 5 min, 35 ml of sample was run on 10% PAGE gel after which the gel was fixed, dried, and exposed. A measure of 4 ml of the same product was used for Western blotting using the same anti-Lyn antibody to control for the total protein loaded.
Other reagents
Pertussis toxin, PP2, and PD98059 were obtained from Calbiochem. Wortmannin was obtained from Sigma. The Src (K296R/Y528F)-DN construct in pUSEamp was obtained from Upstate (Waltham, MA, USA) and uses CMV-derived promoter.
